THE MUSCLE LOSS QUESTION This is the biggest concern people have about GLP-1 medications, and it deserves a straight answer
It produces substantial weight loss averaging 15 to 16% over 68 weeks and has well-characterized cardiovascular benefits
What to expect from AOD 9604 Based on the available clinical data, AOD 9604 produces modest weight loss at best
Use a peptide calculator when in doubt, but understanding the underlying principles helps you catch errors before they become problems
The effects that sit outside the trial tables Menstrual-cycle changes are widely discussed in patient communities, including irregular or doubled cycles during rapid loss. Trials did not pre-specify them, so the adverse-event tables cannot estimate incidence
We are highlighting amylin as the hottest new mechanism for obesity, Leerink Partners analysts wrote in a Tuesday note to investors, explaining that amylin mostly works as a satiety signal and affects hedonic aspects of eating. The molecule acts on several regions of the brain to lower the feeling of being rewarded after eating
